What’s New for 2021
As the largest and most comprehensive event to date, we return bigger and better than ever. As the industry now exists with a first ever approved anti-RAS therapy, we are excited to be bringing you more content, more speakers and an all-inclusive platform for you to gain exclusive insights into industry progression and delve into RAS discussions with over 200 RAS dedicated experts.
What is New for 2021?
A Track Dedicated to Validating Robust Combination Strategies – consider the variety of combination therapies being harnessed to optimize treatment success and limit resistance to RAS targeted therapies
Focus Day on Covalent Inhibition – delve into the world of covalent inhibition for the treatment of human diseases, focusing on high value targets beyond RAS proteins and discussing the top challenges in developing effective covalent drugs to accelerate the future of this progressive therapy
Focus on Clinical Trial Updates & Insights – this year, more than ever before, we will provide drug developers and academic leaders the opportunity to share insights into successes and challenges within ongoing and future clinical trials with insight from clinicians, oncologists and biopharma leaders, keeping you up to date on what data you can expect to see through 2021 and beyond
Dedicated Biopharma Partnering Session – With anti-RAS therapies now with the patient, it is more important than ever for collaborations and partnerships to be made. Join this roundtable discussion to hear an array of opinions and voice your perspective to help shape the future of the field as part of this growing community